argenx SE (NASDAQ:ARGX) Given Average Rating of “Moderate Buy” by Brokerages

argenx SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-two analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $639.78.

ARGX has been the subject of several research analyst reports. JMP Securities increased their target price on shares of argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Truist Financial upped their price target on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company lifted their price objective on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th.

Institutional Trading of argenx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp boosted its position in shares of argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,170 shares during the period. FMR LLC grew its position in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Fiera Capital Corp increased its holdings in shares of argenx by 2.2% in the 2nd quarter. Fiera Capital Corp now owns 165,595 shares of the company’s stock valued at $71,212,000 after acquiring an additional 3,506 shares during the period. Simplify Asset Management Inc. raised its position in argenx by 64.0% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after purchasing an additional 944 shares during the last quarter. Finally, Perpetual Ltd acquired a new stake in argenx during the 3rd quarter worth $76,314,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

ARGX stock opened at $626.31 on Monday. argenx has a one year low of $349.86 and a one year high of $644.97. The firm has a market cap of $37.81 billion, a PE ratio of -711.72 and a beta of 0.59. The firm’s 50 day moving average price is $599.42 and its 200-day moving average price is $532.14.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the previous year, the business earned ($1.25) earnings per share. Equities research analysts predict that argenx will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.